Second Circuit Upholds Sanofi Dismissal Despite Omnicare

by Akin Gump Strauss Hauer & Feld LLP

In its first published opinion applying the Supreme Court’s landmark ruling in Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, 135 S. Ct. 1318 (2015), the 2nd Circuit has offered relief to issuers worried about liability for statements of opinions that later turn out to be false. The Sanofi panel concluded that Omnicare does not require that an issuer disclose every fact that might undermine or contradict its optimistic projections. In re Sanofi Sec. Litig., Nos. 15-588-cv, 15-623-cv (Mar. 4, 2016).


In March 2015, the Supreme Court rendered the seminal Omnicare decision, establishing a new framework for determining whether a statement of opinion is actionable under Section 11 of the Securities Act of 1933 (the “Securities Act”). The Supreme Court held that, where an investor has alleged that an issuer omitted material information and thereby rendered a statement of opinion misleading, the investor must identify particular and material facts going to the basis of the opinion of the issuer whose omission makes the opinion statement at issue misleading. This holding altered the standard for opinion liability in the 2nd Circuit, which previously required proof of objective and subjective falsity. See Fait v. Regions Fin. Corp., 655 F.3d 105 (2d Cir. 2011). Omnicare affirmed that liability may arise from either the speaker not holding the stated belief or the speaker’s supporting facts being untrue. Although this opinion significantly altered the landscape of opinion statement liability, the Supreme Court emphasized that meeting its pronounced standard under Omnicare was still “no small task for an investor.” 135 S. Ct. at 1332.

Sanofi, an appeal of two related actions, centered on the optimistic projections that developers of Lemtrada made about securing U.S. Food and Drug Administration (FDA) approval of the potential breakthrough treatment. Sanofi acquired Genzyme, the developer of Lemtrada (a drug used to treat multiple sclerosis), in 2011. As part of its acquisition, Sanofi issued contingent value rights (CVR) to Genzyme shareholders, which entitled the holders to cash payouts when certain milestones, such as FDA approval, were met. Plaintiffs claimed that Sanofi made certain opinion statements in its offering documents and to the market as a whole that artificially inflated the value of the CVRs. Specifically, plaintiffs claimed that certain statements concerning Sanofi’s expectation of FDA approval for Lemtrada and positive results of its clinical trials were misleading, because they omitted the FDA’s repeated warnings to Sanofi regarding its use of single-blind instead of double-blind studies. In November 2013, in anticipation of its upcoming hearing on Sanofi’s application for Lemtrada approval, the FDA released briefing materials that included concerns about the double-blind studies, which led to the value of the CVRs dropping 62 percent. The next month, the FDA denied approval for Lemtrada, causing the CVR value to drop even more. Although the FDA eventually approved Lemtrada, by then, the first CVR milestone payment had already passed. Thereafter, the two sets of plaintiffs sued Sanofi and some of its officers and directors.

Before the Supreme Court’s decision in Omnicare, the district court dismissed both complaints for failure to state a claim. With regard to the allegations of false and misleading opinion statements, the court found that there had been no showing of objective falsity as required under the 2nd Circuit’s pre-Omnicare standard. The 2nd Circuit affirmed and published its opinion primarily to analyze the impact of the intervening Omnicare decision.

The 2nd Circuit Affirms and Explains Omnicare

The 2nd Circuit focused on three categories of allegedly false and misleading opinion statements: (1) statements related to Sanofi’s expectation that the FDA would approve Lemtrada by March 31, 2014; (2) statements made after the tender offer regarding the launch of Lemtrada, including satisfaction with the progress of Lemtrada and the company’s expectation of an FDA decision by the end of 2013; and (3) statements regarding positive opinions on the results of the Lemtrada clinical trials.
At the outset, the 2nd Circuit laid out some parameters of the Omnicare decision. It acknowledged that the Supreme Court itself cautioned against an expansive reading of the decision, noting that a statement of opinion is not necessary misleading when an issuer knows, but fails to disclose, some facts cutting the other way, since “reasonable investors understand that opinions sometimes rest on a weighing of competing facts.” 135 S. Ct. at 1329. Moreover, the Supreme Court recognized that context matters and that opinion statements cannot be viewed and analyzed in a vacuum.

With respect to the first set of opinion statements on expectation of FDA approval, the 2nd Circuit found that the FDA’s interim feedback did not conflict with any reasonable interpretation of Sanofi’s statements. Although the FDA had expressed concern about the use of single-blind studies, the FDA also stated that any deficiency could be overcome if the test results showed “an extremely large effect,” and there was no dispute that the drug’s treatment effect was large. Moreover, the 2nd Circuit again underscored the importance of context in its examination, noting that plaintiffs were sophisticated investors who were (1) well aware that issuers’ projections are synthesized from a variety of information, some of which may be in tension with the ultimate projection; and (2) well accustomed to the customs and practices of the drug industry and would, therefore, fully expect that Sanofi and the FDA were engaged in an ongoing dialogue that necessarily would include differing views on the adequacy of various aspects of the clinical trials. In addition, these statements were made in the offering materials, which the court noted included numerous caveats to the reliability of projections. Thus, these sophisticated investors could not claim ignorance to the intricacies of the pharmaceutical industry drug-approval process.

In addition, Sanofi rejected plaintiffs’ contentions that Omnicare essentially required defendants to disclose all information that runs counter to its expressed opinion. This was the case even though the 2nd Circuit acknowledged that plaintiffs certainly would have been interested in knowing about the FDA feedback, and perhaps would have even acted otherwise had it been disclosed. “Certainly, plaintiffs would have been interested in knowing about the FDA feedback, and perhaps would have acted otherwise had the feedback been disclosed, but Omnicare does not impose liability merely because an issuer failed to disclose information that ran counter to an opinion expressed in the registration statement.” Again relying on the sophistication of the plaintiff investors, the court noted that the FDA had made its preference for double-blind studies publicly well-known, and investors whose complex financial instrument value was tied to FDA approval should keep themselves apprised of the FDA’s positions. “Sophisticated investors, aware of the FDA’s strong preference for double‐blind trials, cannot claim surprise when it is revealed that the FDA meant what it said.”

As to the second set of challenged opinion statements, the 2nd Circuit concluded that they failed to support a claim for many of the same reasons, most notably that no reasonable investor would have inferred that mere statements of confidence—such as feeling “relaxed” or “satisfied”—suggested that the FDA had not engaged in industry-standard dialogue with Sanofi about potential deficiencies in the testing methodology. Further, the opinion statements regarding timing of the FDA approval were not false. Sanofi expected to receive an FDA decision by the end of 2013; indeed, the first decision, albeit a denial, was announced on December 30, 2013.

Finally, Sanofi’s opinions on the positive results of its clinical trials did not rise to the Omnicare standard either. The 2nd Circuit rejected the idea that statements about the effectiveness of Lemtrada could be misleading merely because the FDA disagreed with the conclusion, so long as the issuer had conducted a meaningful inquiry and, in fact, held that view, especially in light of Lemtrada’s global approval and rollout plan.

Sanofi’s Significance

As the first decision to interpret Omnicare in perhaps the most popular venue for securities suits, Sanofi is both anticipated and instructive. The 2nd Circuit has significantly narrowed the interpretation of opinion statement liability: Omnicare does not require issuers and other statement makers to disclose any and all facts that conflict with the stated opinion; rather, statements of opinion must merely “fairly align” with the information in the issuer’s possession at the time.

Three additional aspects of Sanofi are important to keep in mind. First, the 2nd Circuit relied heavily on the sophistication of the plaintiff investors in those cases in finding that the omission of the FDA dialogue did not make defendants’ statements false or misleading. It remains to be seen whether it, or any other court, will conclude differently in a case involving unsophisticated, or less sophisticated, investors. Additionally, Omnicare addressed claims under Section 11 of the Securities Act, while the Sanofi cases involved both Section 11 claims and allegations under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. While not expressly discussed, Sanofi seems to have applied the Omnicare standard across the board to the Exchange Act claims as well, an outcome that practitioners were awaiting. Third, it is noteworthy that the court relied on the public nature of FDA’s concerns about study design, leaving open the possibility of a different outcome if the nature of a regulatory agency’s concerns remained confidential.

The 2nd Circuit has narrowly interpreted the Supreme Court’s Omnicare decision; only time will tell if other circuits will follow suit. For now, issuers in the 2nd Circuit can breathe a sigh of relief: “Plaintiffs’ case essentially boils down to an allegation that the statements were misleading for failure to include a fact that would have potentially undermined defendants’ optimistic projections. But Omnicare imposes no such disclosure requirements on issuers.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Akin Gump Strauss Hauer & Feld LLP | Attorney Advertising

Written by:

Akin Gump Strauss Hauer & Feld LLP

Akin Gump Strauss Hauer & Feld LLP on:

Readers' Choice 2017
Reporters on Deadline

Related Case Law

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at:

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit
  • New Relic - For more information on New Relic cookies, please visit
  • Google Analytics - For more information on Google Analytics cookies, visit To opt-out of being tracked by Google Analytics across all websites visit This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at:

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.